These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 18829880

  • 1. Drug interactions and pharmacogenomics in the treatment of breast cancer and depression.
    Henry NL, Stearns V, Flockhart DA, Hayes DF, Riba M.
    Am J Psychiatry; 2008 Oct; 165(10):1251-5. PubMed ID: 18829880
    [No Abstract] [Full Text] [Related]

  • 2. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6.
    Desmarais JE, Looper KJ.
    J Clin Psychiatry; 2009 Dec; 70(12):1688-97. PubMed ID: 20141708
    [Abstract] [Full Text] [Related]

  • 3. Selective serotonin reuptake inhibitors and adjuvant tamoxifen therapy: risk of breast cancer recurrence and mortality.
    Cronin-Fenton D, Lash TL, Sørensen HT.
    Future Oncol; 2010 Jun; 6(6):877-80. PubMed ID: 20528223
    [No Abstract] [Full Text] [Related]

  • 4. Tamoxifen-SSRIs interaction: clinical manifestations of inhibition and lack of inhibition of CYP2D6.
    Appiani F, Carroll BT, Muñoz C, Trecco J.
    Ann Clin Psychiatry; 2011 May; 23(2):152-3. PubMed ID: 21547277
    [No Abstract] [Full Text] [Related]

  • 5. A hot flash on tamoxifen metabolism.
    Goetz MP, Loprinzi CL.
    J Natl Cancer Inst; 2003 Dec 03; 95(23):1734-5. PubMed ID: 14652227
    [No Abstract] [Full Text] [Related]

  • 6. Antidepressants and tamoxifen. Drug interactions may increase risk of cancer recurrence or death.
    Harv Ment Health Lett; 2010 Jun 03; 26(12):6-7. PubMed ID: 20669529
    [No Abstract] [Full Text] [Related]

  • 7. Treatment for hot flushes in women receiving tamoxifen.
    Bydder SA, Spry NA.
    Med J Aust; 2002 Sep 02; 177(5):266. PubMed ID: 12197825
    [No Abstract] [Full Text] [Related]

  • 8. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.
    Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, Blanchard R, Nguyen A, Ullmer L, Hayden J, Lemler S, Weinshilboum RM, Rae JM, Hayes DF, Flockhart DA.
    J Natl Cancer Inst; 2005 Jan 05; 97(1):30-9. PubMed ID: 15632378
    [Abstract] [Full Text] [Related]

  • 9. Tamoxifen pharmacogenetics moves closer to reality.
    Garber K.
    J Natl Cancer Inst; 2005 Mar 16; 97(6):412-3. PubMed ID: 15770000
    [No Abstract] [Full Text] [Related]

  • 10. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
    Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA.
    J Natl Cancer Inst; 2003 Dec 03; 95(23):1758-64. PubMed ID: 14652237
    [Abstract] [Full Text] [Related]

  • 11. Genetics examined in tamoxifen's effectiveness: recurrence warning urged for labeling.
    Young D.
    Am J Health Syst Pharm; 2006 Dec 01; 63(23):2286, 2296. PubMed ID: 17105997
    [No Abstract] [Full Text] [Related]

  • 12. Successful duloxetine use to prevent venlafaxine withdrawal symptoms.
    Hsiao MC, Liu CY.
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb 15; 32(2):576. PubMed ID: 17889418
    [No Abstract] [Full Text] [Related]

  • 13. Biological perspectives. Serotonin and norepinephrine reuptake inhibitors (SNRIs): venlafaxine and duloxetine.
    Lee SI, Keltner NL.
    Perspect Psychiatr Care; 2006 May 15; 42(2):144-8. PubMed ID: 16677140
    [No Abstract] [Full Text] [Related]

  • 14. Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen.
    Binkhorst L, Mathijssen RH, van Herk-Sukel MP, Bannink M, Jager A, Wiemer EA, van Gelder T.
    Breast Cancer Res Treat; 2013 Jun 15; 139(3):923-9. PubMed ID: 23760858
    [Abstract] [Full Text] [Related]

  • 15. Tamoxifen, antidepressants, and CYP2D6: the conundrum continues.
    Holzman D.
    J Natl Cancer Inst; 2009 Oct 21; 101(20):1370-1. PubMed ID: 19797723
    [No Abstract] [Full Text] [Related]

  • 16. Menopausal symptoms following tamoxifen treatment for breast cancer.
    Barton DL.
    Oncology (Williston Park); 2008 Apr 21; 22(4 Suppl Nurse Ed):46-8. PubMed ID: 19856564
    [Abstract] [Full Text] [Related]

  • 17. Serotonin toxicity in a CYP2D6 poor metabolizer, initially diagnosed as a drug-resistant major depression.
    Gressier F, Ellul P, Dutech C, Ait Tayeb AEK, Monfort J, Corruble E, Becquemont L, Hardy P, Verstuyft C.
    Am J Psychiatry; 2014 Aug 21; 171(8):890. PubMed ID: 25082493
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Serotonin-noradrenaline reuptake inhibitors(SNRIs)].
    Ishigooka J.
    Nihon Rinsho; 2001 Aug 21; 59(8):1523-9. PubMed ID: 11519152
    [Abstract] [Full Text] [Related]

  • 20. PharmGKB summary: venlafaxine pathway.
    Sangkuhl K, Stingl JC, Turpeinen M, Altman RB, Klein TE.
    Pharmacogenet Genomics; 2014 Jan 21; 24(1):62-72. PubMed ID: 24128936
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.